The tech workplace in 2026: remote, hybrid, and surprisingly human
Four years after the pandemic reshuffled where we work, a new equilibrium has emerged.
How the internet killed genre and why that’s actually good for music
The collapse of genre as a marketing category has produced the most sonically diverse pop charts in history.
TikTok’s cultural dominance is waning — and nobody agrees on what comes next
After the US near-ban, TikTok's share of under-25 video consumption has dropped from 67% to 54%.
The newsletter economy: why paid writers are the new record labels
Substack and Beehiiv now support over 800 writers earning more than $100,000 annually.
The protein folding revolution, three years later: what AlphaFold actually changed
DeepMind's structure prediction tool has been used in 2 million research projects.
Ozempic’s patent cliff is about to change the global drug market
Semaglutide's primary patents expire between 2026 and 2031, opening the market to biosimilars.
GLP-1 drugs are now being used for addiction. The research is startling.
Semaglutide and tirzepatide are showing strong efficacy against alcohol, nicotine, and opioid addiction in early trials.
mRNA flu vaccines are coming — here’s what the trials show
After COVID mRNA vaccines, Moderna and Pfizer have completed Phase 3 trials for influenza with substantially better efficacy.
The longevity startup that thinks it can reverse aging by 20 years — and has data
Altos Labs' first human trial data shows statistically significant improvement on biological age markers.
CRISPR’s first approved gene therapy for sickle cell disease: one year in
Vertex and CRISPR Therapeutics' Casgevy is now in the hands of 340 patients.